Company intelligence / Profile preview

Rappta Therapeutics

Helsinki, Uusimaa, Finlandrappta-therapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Developing first-in-class anti-cancer molecular glues that reactivate protein phosphatase 2A (PP2A), a key tumor suppressor. The company has developed compounds that act as a glue to allow the three subunits of PP2A to bind together, restoring its tumor suppressive function.

Therapeutic areas: Oncology
Modalities: Small moleculesMolecular glues
Industry: Biotech

Partnerships

SpringWorks Therapeutics (global license agreement for RPT04402 as of January 15, 2025)

Beyond the preview

Go deeper on Rappta Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rappta Therapeutics.

Explore the full profile